Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Stabilization priorities
Airway risk
Rapidly worsening agitation
Refractory hyperthermia
Progressive rigidity
Breathing support
Hypoventilation after sedatives
Aspiration risk with vomiting
Circulation support
Hypotension from dehydration
Shock from severe hyperthermia
Trigger recognition
Recent serotonergic exposure
Dose increase
Drug interaction
Overdose
Time zero
Symptom onset within 24 hours of exposure change
Severity stratification
Severity categories
Mild
Tremor
Hyperreflexia
Mild agitation
Afebrile or low-grade fever
Moderate
Marked agitation
Sustained clonus
Hyperthermia 38.0-40.0 C
Autonomic instability
Severe
Hyperthermia >40.0 C
Delirium
Generalized rigidity
Rapid clinical deterioration
Seizure
Coma
Key bedside signs
Neuromuscular hyperactivity pattern
Inducible clonus
Ankle clonus
Ocular clonus
Spontaneous clonus
Sustained rhythmic jerks
Hyperreflexia
Lower extremities predominant
Tremor
Coexisting hyperreflexia
Rigidity
Severe cases
Mydriasis
With diaphoresis
Diaphoresis
With agitation
Escalation triggers
Immediate escalation criteria
Temperature >= 40.0 C
Resuscitation bay
Critical care consult
Refractory agitation
High-dose benzodiazepine requirement
Seizure
Continuous monitoring
Rhabdomyolysis concern
Rising creatine kinase trend
Metabolic acidosis
Rising lactate
Organ failure signs
Oliguria
Hypoxia
Coagulopathy
History
Exposure timeline
Serotonergic exposure pattern
New serotonergic medication
Start date
First dose time
Dose increase
Date and magnitude
Co-ingestion
Multiple serotonergic agents
Overdose
Estimated amount
Time of ingestion
Drug interaction
MAOI combined with SSRI or SNRI
MAOI combined with linezolid
MAOI combined with methylene blue
Onset window
Symptoms within 6 hours
Symptoms within 24 hours
Medication and substance list
High-risk agents
SSRIs
Fluoxetine
Sertraline
Citalopram
Escitalopram
Paroxetine
Fluvoxamine
SNRIs
Venlafaxine
Desvenlafaxine
Duloxetine
MAOIs
Phenelzine
Tranylcypromine
Selegiline
Isocarboxazid
Serotonergic analgesics
Tramadol
Meperidine
Fentanyl
Methadone
Serotonergic antiemetics
Ondansetron
Metoclopramide
Antimicrobials
Linezolid
Migraine therapies
Triptans
OTC and supplements
Dextromethorphan
St John’s wort
Recreational substances
MDMA
Cocaine
Amphetamines
Other
Lithium
Buspirone
Trazodone
Mirtazapine
Symptom pattern
Core symptom clusters
Mental status change
Anxiety
Agitation
Delirium
Confusion
Autonomic hyperactivity
Diaphoresis
Tachycardia
Hypertension
Hyperthermia
Diarrhea
Vomiting
Neuromuscular hyperactivity
Tremor
Clonus
Hyperreflexia
Myoclonus
Rigidity
Risk factors and pitfalls
Higher risk contexts
Polypharmacy
Multiple serotonergic prescriptions
Recent hospitalization
Linezolid exposure
Methylene blue exposure
Medication adherence changes
Restart after interruption
Drug metabolism modifiers
CYP inhibitors co-prescribed
Diagnostic pitfalls
Attribution to anxiety alone
Mislabeling as withdrawal
Missing ocular clonus
Focusing on fever without clonus
Physical Exam
Vital signs and monitoring
Physiologic instability
Temperature trend
Hyperthermia threshold awareness
Heart rate
Persistent tachycardia
Blood pressure
Labile hypertension
Hypotension after sedation
Respiratory rate
Hyperventilation
Oxygen saturation
Aspiration risk marker
Neurologic exam focus
Neuromuscular findings
Clonus
Spontaneous clonus
Inducible clonus
Ocular clonus
Reflexes
Hyperreflexia
Lower extremity predominance
Tone
Rigidity
Increased tone
Tremor
Fine tremor
Myoclonus
Multifocal jerks
Pupils
Mydriasis
Mental status
Agitation
Delirium
Coma
Autonomic and systemic findings
Autonomic features
Diaphoresis
Profuse sweating
Skin
Flushed
GI findings
Hyperactive bowel sounds
Diarrhea
Complication screening
Trauma signs
Falls during agitation
Compartment concern
Severe muscle pain with swelling
PITFALLS
Exam pitfalls
Clonus absent after heavy sedation
Rigidity can mimic NMS in severe cases
Hyperreflexia may be subtle in older adults
Co-ingestions can blur typical pattern
Differential Diagnosis
Life threats and mimics
Hyperthermia syndromes
Neuroleptic malignant syndrome
Dopamine antagonist exposure
Lead-pipe rigidity
Slower onset over days
ICD-10 G21.0
Malignant hyperthermia
Volatile anesthetic exposure
Succinylcholine exposure
Severe rigidity
Heat stroke
Environmental heat exposure
Exertional collapse
Toxicologic mimics
Anticholinergic toxidrome
Dry skin
Urinary retention
Absent bowel sounds
Sympathomimetic toxidrome
Cocaine
Amphetamines
Prominent diaphoresis
Withdrawal syndromes
Alcohol withdrawal
Benzodiazepine withdrawal
Infectious and CNS etiologies
Meningitis
Neck stiffness
Photophobia
Encephalitis
Focal deficits
Seizure
Endocrine and metabolic
Thyroid storm
Hyperthyroid history
Goiter
Hypoglycemia
Altered mental status
Neurologic emergencies
Status epilepticus
Persistent convulsive activity
Intracranial hemorrhage
Focal deficit
Sudden severe headache
Coding and terminology
Serotonin syndrome terminology
SNOMED CT concept
Serotonin syndrome
ICD-10 compatible coding
Poisoning by selective serotonin reuptake inhibitors, accidental
Adverse effect of selective serotonin reuptake inhibitors
Poisoning by other antidepressants, accidental
Laboratory Tests
Core safety labs
Initial lab bundle
Electrolytes and renal function
Sodium
Potassium
Creatinine
Bicarbonate
Liver enzymes
AST
ALT
Creatine kinase
Rhabdomyolysis risk
Trend guidance
Glucose
Hypoglycemia exclusion
Complete blood count
Infection support
Alternative diagnosis support
Acid base and perfusion
Metabolic stress labs
Venous blood gas
pH
Lactate
Arterial blood gas
PaCO2 in mmHg
PaO2 in mmHg
Severe hyperthermia ventilation planning
Lactate
Severe agitation marker
Shock marker
Complications and co-ingestions
Complication screening
Urinalysis
Myoglobinuria suggestion
Coagulation studies
DIC concern in severe hyperthermia
Troponin
Demand ischemia concern
Pregnancy test
Reproductive age
Toxicology support
Acetaminophen level
Intentional ingestion concern
Salicylate level
Mixed overdose concern
Ethanol level
Mixed intoxication concern
Urine drug screen
Sympathomimetic co-use support
Limited specificity acknowledgement
Interpretation pitfalls
Lab limitations
No confirmatory serum serotonin test role
Creatine kinase elevation non-specific
Leukocytosis non-specific stress response
Hyperthermia related transaminitis possible
Diagnostic Tests
Scoring Systems
Diagnostic criteria framework
Hunter Serotonin Toxicity Criteria
Serotonergic agent exposure prerequisite
Prescription serotonergic agent
Illicit serotonergic agent
Spontaneous clonus
Diagnostic if present
Inducible clonus plus agitation or diaphoresis
Diagnostic if criteria met
Ocular clonus plus agitation or diaphoresis
Diagnostic if criteria met
Tremor plus hyperreflexia
Diagnostic if criteria met
Hypertonia plus temperature >38.0 C plus ocular clonus or inducible clonus
Diagnostic if criteria met
Sternbach criteria
Serotonergic agent exposure
Recent addition or increase
No other etiology
Infection exclusion
Metabolic exclusion
Clinical feature cluster
Mental status change
Agitation
Myoclonus
Hyperreflexia
Diaphoresis
Shivering
Tremor
Diarrhea
Incoordination
Fever
Evidence framing
Clinical diagnosis predominance
No single confirmatory test
Hunter criteria practical bedside use
Emphasis on clonus
MRI
Neuroimaging role
MRI brain indications
Persistent focal neurologic deficit
Concern for encephalitis
Concern for stroke mimic
Practical limitations
Agitation limits feasibility
Time sensitivity favors stabilization first
CT
CT role
CT head indications
Head trauma concern
New focal deficit
Unexplained coma
CT chest abdomen pelvis considerations
Alternative source for fever concern
Evidence framing
Not diagnostic for serotonin syndrome
Alternative diagnosis evaluation
Ultrasound
Point-of-care ultrasound applications
Cardiac POCUS
Volume status estimate
Hyperdynamic state support
Lung POCUS
Aspiration pneumonitis support
Alternative hypoxia cause support
Bladder ultrasound
Urinary retention support for anticholinergic mimic
Evidence framing
Supportive only
Complication detection
Disposition
Level of care
Admission criteria
Moderate symptoms
Sustained clonus
Autonomic instability
Temperature >= 38.5 C
Severe symptoms
Temperature >= 40.0 C
Delirium
Seizure
Rigidity
Rhabdomyolysis
ICU criteria
Active cooling requirement
High-dose sedative infusion requirement
Intubation
Persistent hemodynamic instability
Observation criteria
Mild symptoms with improvement
Resolution of clonus
Stable vitals
Reliable follow-up
Short half-life exposure
Symptom improvement within 6-12 hours
Discharge readiness
Discharge criteria
Normal mental status baseline
No delirium
No clonus
No inducible clonus
Afebrile
Stable temperature trend
Stable heart rate and blood pressure
No labile instability
Hydration adequate
Oral intake tolerated
Medication plan clarified
Serotonergic agents held
Prescriber follow-up arranged
Treatment
Immediate measures
First-line strategy
Offending agent cessation
All serotonergic agents stopped
Supportive care
IV crystalloid for volume depletion
Electrolyte correction
Sedation
Benzodiazepines as first-line for agitation
Evidence level: Class I (expert consensus) for benzodiazepines in toxicologic agitation
Temperature control
External cooling for hyperthermia
Avoid antipyretics for toxidromic hyperthermia
Benzodiazepines
Benzodiazepine options
Diazepam IV
5-10 mg IV
Repeat every 5-10 minutes to calm sedation
Escalation to higher doses for severe agitation
Lorazepam IV
1-2 mg IV
Repeat every 5-10 minutes to calm sedation
Larger doses for severe agitation
Midazolam IM
5-10 mg IM
Rapid control when no IV access
Monitoring needs
Continuous pulse oximetry
Capnography when available
Prepared airway support
Serotonin antagonism
Cyproheptadine use
Indications
Moderate symptoms despite benzodiazepines
Persistent clonus with autonomic instability
Contraints
Oral route only
Nasogastric route option if intubated
Adult dosing
12 mg PO or NG loading
2 mg every 2 hours until clinical response
Maximum 32 mg per 24 hours
Maintenance after response
8 mg PO or NG every 6 hours
Adverse effects
Sedation
Anticholinergic effects
Evidence level labeling
Class IIb (limited evidence) for cyproheptadine as adjunctive therapy
Cooling and hyperthermia management
Temperature management
External cooling
Evaporative cooling
Ice packs to axilla and groin
Cooling blankets
IV fluids
Volume repletion support for heat generation and sweating losses
Severe hyperthermia pathway
Temperature >= 40.0 C
Aggressive sedation
Intubation consideration
Neuromuscular paralysis consideration
Avoided therapies
Antipyretics
Limited effect in toxidromic hyperthermia
Physical restraints alone
Risk of worsening hyperthermia and rhabdomyolysis
Airway and paralysis for severe cases
Intubation indications
Refractory agitation
Unable to safely manage cooling
Refractory hyperthermia
Temperature >= 40.0 C with ongoing heat generation
Respiratory failure
Hypoventilation after sedation
Seizure complications
Airway protection need
Neuromuscular blockade
Non-depolarizing agent preference
Rocuronium IV 1.0-1.2 mg/kg
Paralysis to stop muscular heat production
Vecuronium IV 0.1 mg/kg
Alternative
Avoided agent
Succinylcholine
Hyperkalemia risk with rhabdomyolysis
Sedation requirement
Deep sedation before paralysis
Continuous analgesia sedation infusion
Evidence level labeling
Class I (expert consensus) for paralysis in life-threatening hyperthermia syndromes with ongoing muscle activity
Blood pressure and heart rate control
Autonomic instability management
Agitation control first
Benzodiazepine escalation
Short-acting agents if needed
Esmolol IV infusion consideration
Avoid in hypotension
Nicardipine IV infusion consideration
Avoid overshoot hypotension
Avoided long-acting agents
Prolonged hypotension risk after resolution
Seizure management
Seizure treatment
Benzodiazepines
Lorazepam IV 0.1 mg/kg
Typical maximum single dose 4 mg
Diazepam IV 0.15-0.2 mg/kg
Typical maximum single dose 10 mg
Refractory seizures
Levetiracetam IV 60 mg/kg
Maximum 4500 mg
Continuous infusion sedation in ICU
Avoided therapy
Phenytoin
Limited efficacy for toxin-mediated seizures
Special Populations
Pregnancy
Pregnancy considerations
Maternal stabilization priority
Oxygenation and perfusion targets
Medication safety framing
Benzodiazepines
Use when clinically required
Fetal monitoring consideration in viable gestation
Cyproheptadine
Limited pregnancy safety data
Consider when benefits outweigh risks
Obstetric collaboration
Continuous fetal monitoring when indicated
Obstetrics consult for moderate to severe cases
Geriatric
Older adult considerations
Baseline polypharmacy risk
Multiple serotonergic prescriptions
Higher sensitivity to sedatives
Lower initial benzodiazepine dosing consideration
Delirium risk
Atypical presentation risk
Less prominent hyperreflexia
Mixed toxidromes more likely
Complication risk
Rhabdomyolysis with prolonged agitation
Aspiration risk
Pediatrics
Pediatric considerations
Weight-based dosing
Benzodiazepines
Lorazepam IV 0.05-0.1 mg/kg
Repeat dosing based on response
Midazolam IM 0.1-0.2 mg/kg
Maximum single dose based on local protocol
Cyproheptadine
0.25 mg/kg per day PO
Divide every 6-8 hours
Maximum 12 mg per day in younger children
Maximum 32 mg per day in adolescents
High-risk exposures
Accidental ingestion
SSRI dose changes
Dextromethorphan co-use
Monitoring intensity
Lower threshold for admission with sustained clonus
Background
Epidemiology
Epidemiologic features
Common cause category
Drug interaction
Polypharmacy
Overdose
Onset timing pattern
Usually within 6 hours of exposure change
Usually within 24 hours of exposure change
Under-recognition risk
Mild cases missed
Misclassification as anxiety or withdrawal
Pathophysiology
Mechanism summary
Excess serotonergic activity
Central 5-HT receptor overactivation
Peripheral 5-HT receptor overactivation
Neuromuscular hyperactivity mechanism
Increased spinal motor neuron activity
Hyperthermia mechanism
Increased muscle activity heat production
Autonomic dysregulation
Clinical triad framework
Mental status change
Autonomic hyperactivity
Neuromuscular hyperactivity
Therapeutic Considerations
Treatment principles
Supportive care dominance
Agent cessation
Sedation
Cooling
Antidote role
Cyproheptadine as adjunct
Oral route limitation
Hyperthermia priorities
Muscle activity suppression
External cooling
Early ICU pathway for severe cases
Evidence labeling
Class I (expert consensus) for supportive care and benzodiazepines
Class IIb (limited evidence) for cyproheptadine adjunct
Patient Discharge Instructions
copy discharge instructions
Discharge instructions
Diagnosis explanation
Medication reaction from excess serotonin activity
Medication plan
Do not restart serotonergic medications until prescriber review
Avoid new OTC cough or supplement products without pharmacist review
Hydration and rest
Oral fluids
Avoid intense exercise for 48 hours
Return to ED immediately
Fever
New confusion
Severe agitation
Shaking or uncontrollable jerking
Stiffness
Fainting
Chest pain
Shortness of breath
Dark urine
Decreased urination
Follow-up
Prescriber contact within 24-72 hours
Medication reconciliation review
References
Clinical criteria and landmark descriptions
Core references
Hunter Serotonin Toxicity Criteria publication
Validation and bedside criteria emphasis on clonus
Sternbach criteria original description
Earlier diagnostic framework
Toxicology and critical care reviews
Supportive care and benzodiazepines as first-line
Case series and consensus statements
Cyproheptadine adjunct use
Professional guidance and evidence framing
Evidence framing references
Emergency medicine toxicology consensus
Supportive care as primary therapy
Critical care hyperthermia management principles
Sedation plus paralysis for life-threatening hyperthermia
Medication safety resources
Serotonergic interaction warnings for linezolid and MAOIs
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.